Antibody therapy for COVID-19

PURPOSE OF REVIEW: To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. RECENT FINDINGS: Limited clinical effect of classical passive immunotherapy (plasma therapy, hyper...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammarström, Lennart, Marcotte, Harold, Piralla, Antonio, Baldanti, Fausto, Pan-Hammarström, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577309/
https://www.ncbi.nlm.nih.gov/pubmed/34570010
http://dx.doi.org/10.1097/ACI.0000000000000787
_version_ 1784596044091228160
author Hammarström, Lennart
Marcotte, Harold
Piralla, Antonio
Baldanti, Fausto
Pan-Hammarström, Qiang
author_facet Hammarström, Lennart
Marcotte, Harold
Piralla, Antonio
Baldanti, Fausto
Pan-Hammarström, Qiang
author_sort Hammarström, Lennart
collection PubMed
description PURPOSE OF REVIEW: To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. RECENT FINDINGS: Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results. SUMMARY: Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results.
format Online
Article
Text
id pubmed-8577309
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85773092021-11-09 Antibody therapy for COVID-19 Hammarström, Lennart Marcotte, Harold Piralla, Antonio Baldanti, Fausto Pan-Hammarström, Qiang Curr Opin Allergy Clin Immunol PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles PURPOSE OF REVIEW: To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. RECENT FINDINGS: Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results. SUMMARY: Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results. Lippincott Williams & Wilkins 2021-12 2021-09-27 /pmc/articles/PMC8577309/ /pubmed/34570010 http://dx.doi.org/10.1097/ACI.0000000000000787 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles
Hammarström, Lennart
Marcotte, Harold
Piralla, Antonio
Baldanti, Fausto
Pan-Hammarström, Qiang
Antibody therapy for COVID-19
title Antibody therapy for COVID-19
title_full Antibody therapy for COVID-19
title_fullStr Antibody therapy for COVID-19
title_full_unstemmed Antibody therapy for COVID-19
title_short Antibody therapy for COVID-19
title_sort antibody therapy for covid-19
topic PRIMARY IMMUNE DEFICIENCY DISEASE: Edited by M. Teresa de la Morena and Stephen Jolles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577309/
https://www.ncbi.nlm.nih.gov/pubmed/34570010
http://dx.doi.org/10.1097/ACI.0000000000000787
work_keys_str_mv AT hammarstromlennart antibodytherapyforcovid19
AT marcotteharold antibodytherapyforcovid19
AT pirallaantonio antibodytherapyforcovid19
AT baldantifausto antibodytherapyforcovid19
AT panhammarstromqiang antibodytherapyforcovid19

Ejemplares similares